NEW YORK – Life science firm Azenta said Thursday that it will be providing proteomic profiling data for 20,000 individuals participating in the FinnGen Finnish biobank project.
Azenta will perform the proteomic profiling in collaboration with the University of Helsinki, which leads the FinnGen project, using Olink's Explore technology.
Financial and other terms of the agreement were not disclosed.
The FinnGen project has collected and is analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.
"FinnGen's adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease," Aarno Palotie, FinnGen's scientific director from the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, said in a statement. "By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets."
"As one of the collaborators in the FinnGen project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come," Ginger Zhou, senior VP and general manager of Genewiz multiomics and synthesis solutions at Azenta, said in a statement. "Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments."